TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention
| Autor: | Emanuela De Cillis, Stefano Favale, Martino Pepe, Annagrazia Cecere, O. Burattini, Alessandro Santo Bortone, Alessandro Cafaro, Luca Amato, Nicola Forzati, Francesco Giardinelli |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Prasugrel business.industry medicine.medical_treatment Percutaneous coronary intervention Clopidogrel P2Y12 Internal medicine medicine Cardiology In patient cardiovascular diseases Cardiology and Cardiovascular Medicine business Ticagrelor circulatory and respiratory physiology medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 72:B322 |
| ISSN: | 0735-1097 |
| Popis: | Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more intense effect when compared to clopidogrel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|